Some have argued that buprenorphine should be a first line for cancer pain [21]; however, a prior systematic review that examined the effectiveness of buprenorphine for cancer pain included data from randomized controlled trials (RCT) only, and its results did not find sufficient evidence to prioritize buprenorphine over full MOR agonists [22]. Here, OPRM1 is linked to cancer.